Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario La Paz (19)

2024

  1. Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antivirals

    AIDS reviews, Vol. 25, Núm. 4, pp. 162-172

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

2019

  1. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

2017

  1. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  2. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  3. Human T-Lymphotropic Virus Infection in Hepatitis C Virus-Antibody Positive Patients in Spain

    AIDS Research and Human Retroviruses, Vol. 33, Núm. 10, pp. 1013-1017

  4. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663

  5. Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C

    Antiviral Therapy, Vol. 22, Núm. 7, pp. 571-575

  6. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials

    Antiviral Therapy, Vol. 22, Núm. 4, pp. 307-312

2016

  1. Delta hepatitis: New approaches to therapy

    Future Virology, Vol. 11, Núm. 3, pp. 197-205

2015

  1. Dolutegravir for the treatment of HIV-2 infection

    Journal of Clinical Virology, Vol. 64, pp. 12-15

  2. The burden of neglected HIV-2 and HTLV-1 infections in Spain

    AIDS Reviews, Vol. 17, Núm. 4, pp. 212-219

  3. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  4. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

2012

  1. Antiviral effect of raltegravir on HTLV-1 carriers

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 1, pp. 218-221

  2. Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A

    Journal of General Virology, Vol. 93, Núm. 4, pp. 889-899

  3. Prevalence of xenotropic murine leukemia virus-related virus infection in different risk populations in Spain

    AIDS Research and Human Retroviruses, Vol. 28, Núm. 9, pp. 889-894

  4. Short communication: RNASEL alleles and susceptibility to infection by human retroviruses and hepatitis viruses

    AIDS Research and Human Retroviruses, Vol. 28, Núm. 10, pp. 1259-1261